Abstract:Many patients filling high-intensity statins following a myocardial infarction do not continue taking this medication with high adherence for 2 years postdischarge. Interventions are needed to increase high-intensity statin use and adherence after myocardial infarction.
“…In a recent study by Jia et al, post-PCI patients randomly assigned to more frequent follow-up visits with a physician had higher rates of medication adherence (56 vs. 46%, p < 0.001), as well as lower rates of MACE, than those assigned to the “usual care” group [41]. Supporting this finding, visiting with a cardiologist after MI discharge has been associated with 10–20% higher adherence to high-dose statin therapy at 6 months as well as similarly increased rates of persistence at 2 years [34]. Timing may be important in light of the observation of an association between patients who visit a provider within 6 weeks of MI discharge and a 5–10% higher (in absolute terms) adherence to post-MI therapies both short and long term [42•].…”
Section: Health Team and System-related Factorsmentioning
confidence: 91%
“…This likely explains why prescription drug coverage has previously and, in recent literature, continues to be positively associated with medication adherence. In contrast, a lack of medication coverage is negatively associated with adherence [32–34]. Consistent with these observations, Choudhry et al demonstrated that eliminating copayments for medications resulted in a 4–6% absolute increase in rates of medication adherence ( P < 0.001) [35].…”
Section: Socioeconomic Factorsmentioning
confidence: 94%
“…Polypharmacy is common among CAD patients and continues to be associated with significantly lower rates of adherence [33, 34]. While pill boxes discussed above are the current mainstays for addressing polypharmacy, the so-called “polypill,” consisting of multiple pharmacologic therapies formulated together in one pill, has been heralded as a panacea for polypharmacy.…”
Purpose of Review
Non-adherence to medications for the secondary prevention of myocardial infarction (MI) is a major contributor to morbidity and mortality in these patients. This review describes recent advances in promoting adherence to therapies for coronary artery disease (CAD).
Recent Findings
Two large randomized controlled trials to “incentivize” adherence were somewhat disappointing; neither financial incentives nor “peer pressure” successfully increased rates of adherence in the post-MI population. Patient education and provider engagement appear to be critical aspects of improving adherence to CAD therapies, where the provider is a physician, pharmacist, or nurse and follow-up is performed in person or by telephone. Fixed-dose combinations of CAD medications, formulated as a so-called “polypill,” have shown some early efficacy in increasing adherence. Technological advances that automate monitoring and/or encouragement of adherence are promising but seem universally dependent on patient engagement. For example, medication reminders via text message perform better if patients are required to respond. Multifaceted interventions, in which these and other interventions are combined together, appear to be most effective.
Summary
There are several available types of proven interventions through which providers, and the health system at large, can advance patient adherence to CAD therapies. No single intervention to promote adherence will be successful in all patients. Further study of multifaceted interventions and the interactions between different interventions will be important to advancing the field. The goal is a learning healthcare system in which a network of interventions responds and adapts to patients’ needs over time.
“…In a recent study by Jia et al, post-PCI patients randomly assigned to more frequent follow-up visits with a physician had higher rates of medication adherence (56 vs. 46%, p < 0.001), as well as lower rates of MACE, than those assigned to the “usual care” group [41]. Supporting this finding, visiting with a cardiologist after MI discharge has been associated with 10–20% higher adherence to high-dose statin therapy at 6 months as well as similarly increased rates of persistence at 2 years [34]. Timing may be important in light of the observation of an association between patients who visit a provider within 6 weeks of MI discharge and a 5–10% higher (in absolute terms) adherence to post-MI therapies both short and long term [42•].…”
Section: Health Team and System-related Factorsmentioning
confidence: 91%
“…This likely explains why prescription drug coverage has previously and, in recent literature, continues to be positively associated with medication adherence. In contrast, a lack of medication coverage is negatively associated with adherence [32–34]. Consistent with these observations, Choudhry et al demonstrated that eliminating copayments for medications resulted in a 4–6% absolute increase in rates of medication adherence ( P < 0.001) [35].…”
Section: Socioeconomic Factorsmentioning
confidence: 94%
“…Polypharmacy is common among CAD patients and continues to be associated with significantly lower rates of adherence [33, 34]. While pill boxes discussed above are the current mainstays for addressing polypharmacy, the so-called “polypill,” consisting of multiple pharmacologic therapies formulated together in one pill, has been heralded as a panacea for polypharmacy.…”
Purpose of Review
Non-adherence to medications for the secondary prevention of myocardial infarction (MI) is a major contributor to morbidity and mortality in these patients. This review describes recent advances in promoting adherence to therapies for coronary artery disease (CAD).
Recent Findings
Two large randomized controlled trials to “incentivize” adherence were somewhat disappointing; neither financial incentives nor “peer pressure” successfully increased rates of adherence in the post-MI population. Patient education and provider engagement appear to be critical aspects of improving adherence to CAD therapies, where the provider is a physician, pharmacist, or nurse and follow-up is performed in person or by telephone. Fixed-dose combinations of CAD medications, formulated as a so-called “polypill,” have shown some early efficacy in increasing adherence. Technological advances that automate monitoring and/or encouragement of adherence are promising but seem universally dependent on patient engagement. For example, medication reminders via text message perform better if patients are required to respond. Multifaceted interventions, in which these and other interventions are combined together, appear to be most effective.
Summary
There are several available types of proven interventions through which providers, and the health system at large, can advance patient adherence to CAD therapies. No single intervention to promote adherence will be successful in all patients. Further study of multifaceted interventions and the interactions between different interventions will be important to advancing the field. The goal is a learning healthcare system in which a network of interventions responds and adapts to patients’ needs over time.
“…At 182 and 730 days after discharge, 54.8% and 36.7% of beneficiaries, respectively, remained on high‐intensity statins with high adherence. Whites, beneficiaries with fewer comorbidities, low‐income subsidy, and a high‐intensity statin fill prior to their MI and those who had cardiac rehabilitation and cardiologist visits post‐MI were more likely to remain on high‐intensity statins with high adherence …”
“…However, as the authors themselves concede, their results are somewhat dependent on how they define discontinuation, reinitiation, and persistence—definitions which are not consistent throughout the literature. 12,15 More concerning is the large number of patients excluded by the current analysis. From an initial sample of >900 000 patients, >500 000 were excluded for not having comprehensive Medicare coverage (A+B+D−Health Maintenance Organization).…”
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.